Mark Parry
Senior Scientific Director Intertek
Mark Parry has worked with Intertek for over 24 years after graduating from Cambridge University and currently works as the Senior Scientific Director supporting the wide range of analytical, formulation, product development, and research activities across the company.
Mark has worked in a range of pharmaceutical analysis and formulation development areas with a focus on inhaled and nasal drug products. Mostly working in the pre-approval stages, Mark’s background includes extensive experience with product and formulation development, as well as method development and validation, IVBE studies, and pharmaceutical development activities for a wide range of clients across the pharmaceutical industry.
Mark is part of the DDL committee, as well as a member and chair of several EPAG and IPAC-RS working groups. Mark is also an elected member of the RSC Inclusion and Diversity Committee. He routinely presents at conferences as well as contributing to articles, research papers, and posters on a range of respiratory topics.
Seminars
- Initial screening of Ondansetron formulations for nasal delivery
- Evaluation of nose-to-brain (N2B) and conventional nasal delivery devices
- Early formulation–device performance insights and key considerations for further development
